UNSPSC 51123903: Rilozarone

This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E521I6380L. European Medicines Agency schedules Rilozarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10318MIG. Rilozarone generally arises in the molecular formula C32H36BRCLN2O2.

UNSPSC 51123903 Rilozarone, a Commodity code, represents state and local procurement of specific pharmaceutical products for emergency medical services, public health programs, and cooperative purchasing networks. Recent solicitations show state and local governments buying branded and generic medications—Advanced Life Support drugs, multi-source generics, and over-the-counter products—through both single-jurisdiction and multistate cooperative purchasing arrangements. The scope includes supply chain requirements such as expiration-date warranties, cold-chain logistics, compliance with FDA and OSHA standards, and direct manufacturer-to-wholesaler relationships. Issuing bodies span city fire rescue departments, state health and human services commissions, and cooperative purchasing alliances representing multiple states and local jurisdictions. The City of Tampa's Fire Rescue operation and the Texas Health and Human Services Commission represent direct end-user procurement, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinates purchasing across participating state and local facilities in multiple states including Oregon.

Recent activity concentrates in Florida and Texas, with multistate cooperative procurement extending to Oregon and other MMCAP member jurisdictions. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications—Labetalol, Epinephrine, Adenosine, and Diltiazem—with a response deadline of April 8, 2026, and an estimated contract value of $40,000, featuring a 5 percent bid discount for Small Local Business Enterprise participation. The Texas HHS Commission posted an RFI (No. HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels—an exploratory procurement for future formal solicitation. MMCAP released an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with contract effectiveness targeted for July 1, 2026, and evaluation weighted 75 percent on price competitiveness.